Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

EC advisors call for update of GM legislation

The seven advisiors of the EU Commission (SAM) call on the European Commission (EC) to revise the existing GMO directive 2001/18/EC because the...

Afyren raises €21m to launch production plant

Together with its historical shareholders AFY Partners and Sofimac Régions Afyren has raised more than €60m to move its zero-waste fermentation...

IPO: Marinomed sets offer price

According to the Austrian formulation specialist, 299,000 new bearer shares were placed with investors consisting of 260,000 shares from the base...

Tissue specific tumour transition needs few cells

Anja Voss-Böhme from University Dresden and researchers at the German Cancer Center in Heidelberg used a model that links epigenetic and genetic...

Merry Christmas and a Happy New Year

Boehringer and Epizyme enter US$300m deal

According to BI, more than half of cancers can stem from functional errors in epigenetic modification, which diagnostically characterise the patient...

New cheap CRS-blockers at the horizon

In mice, the team headed by Bert Vogelstein and Shibin Zhou from Johns-Hopkins University in Baltimore demonstrated that severe...